- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Survey of Participants from Landmark GRACE Trial Provides Patients’ Perspectives from an HIV Clinical Study
Most Survey Participants Would Recommend Joining a Study to Others
Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017
Fastest growing Top 10 pharmaceutical business in the U.S., Europe & Japan in 2012, 12 consecutive quarters of operational sales growth in the Pharmaceuticals segment• Current plans are for new products to account for nearly half of the total sales in the Pharmaceuticals segment by 2017, Continued commitment to addressing most serious global unmet medical needs to help transform the lives of patients, R&D strategy builds on strong internal research and external innovation, Late stage pipeline features potential breakthrough therapies that will help transform patient care and sustain future growth
SIMPONI® (GOLIMUMAB) Receives FDA Approval For Ulcerative Colitis
First and Only Subcutaneous Biologic Treatment Approved to Induce and Maintain Clinical Response and Improve Endoscopic Appearance of the Mucosa During Induction
Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. Food and Drug Administration
Second Janssen oncology compound to receive Breakthrough Therapy Designation
Janssen Submits Marketing Authorisation Application for Simeprevir (TMC435) to the European Medicines Agency for the Treatment of Adult Patients with Chronic Hepatitis C Genotype 1 or Genotype 4
Submission Based on Phase III Data in HCV Patients, Including Patients with Compensated Liver Disease